0001551986-18-000017.txt : 20180828
0001551986-18-000017.hdr.sgml : 20180828
20180828163309
ACCESSION NUMBER: 0001551986-18-000017
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180824
FILED AS OF DATE: 20180828
DATE AS OF CHANGE: 20180828
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Almenoff June Sherie
CENTRAL INDEX KEY: 0001492647
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37797
FILM NUMBER: 181041974
MAIL ADDRESS:
STREET 1: C/O FURIEX PHARMACEUTICALS, INC.
STREET 2: 3900 PARAMOUNT PARKWAY, SUITE 150
CITY: MORRISVILLE
STATE: NC
ZIP: 27560
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: INNOVATE BIOPHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0001551986
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 8480 HONEYCUTT ROAD
STREET 2: SUITE 120
CITY: RALEIGH
STATE: NC
ZIP: 27615
BUSINESS PHONE: 919-275-1933
MAIL ADDRESS:
STREET 1: 8480 HONEYCUTT ROAD
STREET 2: SUITE 120
CITY: RALEIGH
STATE: NC
ZIP: 27615
FORMER COMPANY:
FORMER CONFORMED NAME: Monster Digital, Inc.
DATE OF NAME CHANGE: 20150930
FORMER COMPANY:
FORMER CONFORMED NAME: Tandon Digital, Inc.
DATE OF NAME CHANGE: 20120611
4
1
wf-form4_153548837301387.xml
FORM 4
X0306
4
2018-08-24
0
0001551986
INNOVATE BIOPHARMACEUTICALS, INC.
INNT
0001492647
Almenoff June Sherie
C/O INNOVATE BIOPHARMACEUTICALS, INC.
8480 HONEYCUTT ROAD, SUITE 120
RALEIGH
NC
27615
0
1
0
0
COO and Chief Medical Officer
Common stock
2018-08-24
4
P
0
100
4.85
A
100
I
By Meadowlark Management LLC
Common stock
2018-08-24
4
P
0
400
4.99
A
500
I
By Meadowlark Management LLC
Common stock
2018-08-27
4
P
0
47
4.90
A
547
I
By Meadowlark Management LLC
Common stock
2018-08-27
4
P
0
253
4.96
A
800
I
By Meadowlark Management LLC
Common stock
2018-08-27
4
P
0
100
4.94
A
900
I
By Meadowlark Management LLC
Common stock
2018-08-24
4
P
0
500
4.85
A
1400
I
By Meadowlark Management LLC
The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for the purposes of Section 16 or for any other purpose.
/s/ Kendyle Woodard, as Attorney-in-Fact
2018-08-28